Welcome to third quarterly external newsletter of 2025!
Thank you for signing up on our website to receive this newsletter, we hope you enjoy learning more about the important progress we've made towards our mission since the end of June.
Since we know you love science and technology, why not follow us daily on our social media channels and never miss our news, events, awards, and publications: on X/Twitter, Facebook, Instagram, Threads, and Bluesky!
It's been a remarkably productive quarter, with new awards & grants to researchers, new clinical trials initiated, news media coverage of our colleagues, exciting events, and published research in top-tier scientific journals. A sample of this work is highlighted below. 
This important work is only possible because of the financial support we receive from foundations, government agencies, corporate partners, and individual donors. We invite you to consider donating to our mission to advance science and speed new treatments to patients.
Thank you again for your interest in our work!
Sincerely,
Olivier Elemento, Ph.D.
News Coverage & Awards 
"A $1.1 million grant from the parent-caregiver-led Rare Bird Foundation to Weill Cornell Medicine investigators, including Dr. M. Elizabeth Ross from the Feil Family Brain and Mind Research Institute and the EIPM, is supporting the launch of a natural history study for a rare neurodevelopmental disorder that causes developmental delays and seizures called MEF2C Haploinsufficiency syndrome (MCHS)." Weill Cornell Medicine Newsroom, July 29th.
The article "Targeting MAPK and PI3K/mTOR pathways halts ovarian cancer growth," was published in Drug Target Review on July 16th, and quoted our colleague Dr. Benjamin Hopkins discussing his recent research published in Cell Reports Medicine (below). The same research paper was covered in news articles by StudyFinds on July 14th and Inside Precision Medicine on July 9th.
Dr. Allyson Ocean participated in a recent Survivor Net article on the challenges of treating patients with pancreatic cancer, like ‘Bachelorette’ Star Hannah Brown.
Dr. Elemento also published the Human-in-the-loop Substack articles: "From Clinic to Code: A Strategic AI Checklist," on August 12th; and "AI Governance: The Accelerator, Not the Anchor," on August 10th.
Congratulations to our Clinical Director Dr. Cora N. Sternberg on being awarded the title of Faculty Member of the College of the European School of Oncology for the year 2025, in appreciation for her constant contribution to activities organized by the European School of Oncology!
Please join us in congratulating internationally recognized medical oncologist Dr. Allyson J. Ocean on being named the EIPM's new Director of the Early Onset Gastrointestinal Cancer Programeffective August 1st!
Dr. Lisa Newman explains why Triple-negative breast cancer may come back as hormone receptor-positive disease about a third of the time on the September 23rd breast cancer.org podcast.
Dr. Carolina Reduzzi was interviewed for the new article "How Circulating Tumor Cells Can Help Diagnose Cancer Early. Circulating tumor cells allow researchers to detect cancer early, provide an accurate prognosis, monitor progression, and inform personalized medicine," published in The Scientist on September 25th.
Events
The EIPM hosted a Seminar, “Cancer Epigenetics and Epitranscriptomics; from Knowledge to Applications,” presented by Dr. Manel Esteller, Chair of Genetics, School of Medicine at the University of Barcelona on July 22nd.
Director Olivier Elemento, Ph.D. (left) hosted Dr. Parsa Mirhaj (center) from NYU Langone’s Laura and Isaac Perlmutter Cancer Center for his EIPM Precision Medicine Seminar, "Patient Screening and Clinical Trials Matching Using LLMs" on July 17th. Later in the day Dr. Mirhaj and Dr. Adil Ahmed, a machine learning engineer from the Albert Einstein College of Medicine's Department of Medicine to meet our staff and tour of our facilities.
We thank Dr. Elvire Roblin from WCM's Institute for Computational Biomedicine for presenting the EIPM Precision Medicine AI Working Group talk "Leveraging Foundation Modes to Identify Epigenomic Subtypes of Prostate Cancer from Histopathology," on July 18th. 
Congratulations to our 2025 Summer Internship program participants who concluded the summer program by presenting their projects on August 14th! We thank all of our students for their hard work and dedication to the program, and recognize the EIPM and Meyer Cancer Center mentors and staff who contributed so generously of their time to make this another wonderful summer.
Assistant Professor Dr. Daniela Sia from the Division of Liver Diseases in the Department of Medicine at Icahn School of Medicine at Mount Sinai delivered the EIPM Precision Medicine Seminar Series talk "Discovery of Novel Therapeutic Vulnerabilities in Cholangiocarcinoma," on August 7th then toured our labs with Drs. Benjamin Hopkins and Andrea Sboner.
On September 23rd Director Olivier Elemento participated in the National Cancer Institute sponsored virtual event "NCI Cancer AI Conversations." The event was covered in an OncoDaily article on September 19th.
Publications
Our Associate Director for Precision Immunology Dr. Laura Santambrogio recently published three articles: "Age-dependent brain responses to mechanical stress determine resilience in a chronic lymphatic drainage impairment model," was published in The Journal of Clinical Investigation on July 15th.
"Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer," was published in Cell Reports Medicine on July 7th by our EIPM colleagues Drs. Shalini Nath and Benjamin D. Hopkins, with Ufuoma Nuwere, Lamberto De Boni, Director Olivier Elemento, Ph.D., and Dr. Majd Al Assaad from the Pathology and Laboratory Medicine department and the EIPM. 
"A foundational model for in vitro fertilization trained on 18 million time-lapse images," was published in Nature Communications on July 11th by Suraj Rajendran, Eeshaan Rehani, William Phu, Director Olivier Elemento, Ph.D., and Dr. Iman Hajirasouliha.
"PD-1 is requisite for skin TRM cell formation and specification by TGFβ. Thus, PD-1 signaling mediates skin TRM cell specification during immune initiation. These findings may inform therapeutic PD-1 agonist and antagonist use to modulate successful peripheral memory." Nature Immunology, July 29th by Drs. Niroshana Anandasabapathy, Akanksha Verma, and Director Olivier Elemento.
"Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer," was published in Nature Communications on July 1st by Dr. Juan Miguel Mosquera from the Pathology and Laboratory Medicine department and the EIPM, with EIPM colleagues Michael Sigouros, Jyothi Manohar, and Abigail King.
"Redefining druggable targets with artificial intelligence. We highlight the failure of current target taxonomies and the need for benchmarking datasets, and re-evaluate clinical validation for novel AI-driven modalities." Nature Biotechnology commentary by EIPM Director Olivier Elemento, Ph.D., August 19th.
"Artificial Intelligence in Hematology," was published in Blood by Director Olivier Elemento, Ph.D. and colleagues on August 22nd. The paper was also previewed in an OncoDaily Insight blog post by Dr. Elemento on August 24th. 
"Skin biopsies enhance prediction of clinical trajectory in diffuse cutaneous systemic sclerosis," was published in Arthritis & Rheumatology on September 1st by Dr. Niroshana Anandasabapathy with Hiranmayi Ravichandran.
"A spatial long-read approach at near-single-cell resolution reveals developmental regulation of splicing and polyadenylation sites in distinct cortical layers and cell types," was published in Nature Communications on August 29th (too late for last month's newsletter) by Drs. M. Elizabeth Ross and Iman Hajirasouliha. 
"Cancer in a drop: Liquid biopsy highlights from the American Society of Clinical Oncology (ASCO) 2025 annual congress. At the 2025 ASCO Annual Meeting, liquid biopsy emerged as a central theme across multiple sessions, with more than 700 abstracts, investigating the clinical utility of liquid biopsy across a wide range of tumor types and disease stages," was published in The Journal of Liquid Biopsy's September 2025 edition by Dr. Carolina Reduzzi.
"Liquid biopsy in breast cancer: Redefining precision medicine," was published in the September 2025 edition of The Journal of Liquid Biopsy by Drs. Carolina Reduzzi and Scientific Director Massimo Cristofanilli.
"A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy," was published in Future Oncology on September 1st by Clinical Director Dr. Cora N. Sternberg, Dr. Scott T. Tagawa, and colleagues.
# # #